Table 4 Clinical characteristics for all cycles of chemotherapy with and without subsequent nephrotoxicity
From: Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study
Characteristic | Nephrotoxicity (+) | Nephrotoxicity (−) | P value |
|---|---|---|---|
(n = 71) | (n = 371) | ||
BMI (kg/m2) | 20.0 ± 3.3 | 20.6 ± 3.1 | 0.12 |
Systolic blood pressure (mmHg) | 112.0 ± 14.7 | 118.5 ± 15.1 | <0.001 |
Diastolic blood pressure (mmHg) | 68.3 ± 9.7 | 71.6 ± 11.1 | 0.01 |
Antihypertensive medication | 20 (28.2) | 80 (21.6) | 0.22 |
 Calcium channel blockers | 13 (18.3) | 58 (15.7) | 0.60 |
 RAS inhibitors | 14 (19.7) | 43 (11.6) | 0.08 |
 Others | 7 (9.9) | 18 (4.9) | 0.10 |
Combination of anticancer drugs | 54 (76.1) | 299 (80.6) | 0.42 |
Cisplatin dose (mg/m2) | 71.4 ± 10.5 | 68.2 ± 13.3 | 0.03 |
Cumulative cisplatin dose (mg/m2) | 135 ± 83 | 152 ± 101 | 0.13 |
Amount of hydration (mL/day) | 3,441 ± 343 | 3,391 ± 532 | 0.31 |
Diuretics | 66 (93.0) | 345 (93.2) | 0.93 |
Non-solid food | 38 (53.5) | 141 (38.0) | 0.02 |
Decreased food intake (≤50%) | 12 (16.9) | 62 (16.7) | 0.97 |
Laboratory data | |||
 Creatinine (mg/dL) | 0.70 ± 0.20 | 0.74 ± 0.21 | 0.12 |
 CRP (mg/dL) | 1.04 ± 1.65 | 0.66 ± 1.45 | 0.08 |
 Albumin (g/dL) | 3.83 ± 0.46 | 3.87 ± 0.45 | 0.43 |
 Hemoglobin (g/dL) | 12.1 ± 1.6 | 11.9 ± 1.8 | 0.37 |